Project Grant HT94252510644
Award Date
9/1/25
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
The federal Project Grant award of $1,009,054.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research aimed at "Discovery and Therapeutic Targeting of Endogenous Retroviruses in Clear Cell Renal Cell Carcinoma" at Yale University over the period of September 1, 2025 to August 31, 2029. The research project seeks to advance biomedical knowledge and develop innovative treatments for this form of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,130,469 to Yale University to uncover the tumor-immune microenvironmental determinants of immunotherapy response in renal cell carcinoma through ex vivo patient-derived models. The research aims to transform health care for Service Members and the American public through innovative and impactful research investigating medical solutions for the battlefield....
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
This Project Grant award in the amount of $322,371.00 from the Defense Health Agency (DHA) was provided to Yale University on May 15, 2024 under the Military Medical Research and Development program (CFDA 12.420). The award supports the research project "OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR-BASED THERAPIES FOR RENAL CELL CARCINOMA" with a planned completion date of May 14, 2027. The goal of this grant is to advance scientific understanding and therapeutic approaches for...
The Department of the Army Medical Command awarded Yale University a $1,004,997 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund Yale University's pilot development of new forms of chimeric antigen receptor therapies for kidney cancer from August 15, 2021 to August 14, 2024. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through...
The Department of the Army Medical Command awarded a $347,100 project grant to Dana-Farber Cancer Institute, Inc. doing business as Dfci, for the period of March 1, 2022 through February 28, 2025. The grant supports research entitled "Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear Cell Renal Cell Carcinoma" under the Military Medical Research and Development program. This project will investigate medical solutions for clear cell renal cell...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
Yale University received a $1,618,571 project grant award from the Defense Health Agency through the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
The Defense Health Agency awarded Yale University a $837,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "MECHANISM-CENTRIC PREDICTIVE MODELING FOR PROSTATE CANCER". The 3-year grant, running from July 1, 2024 to June 30, 2027, supports Yale's work to develop new predictive modeling approaches for prostate cancer. This research aims to improve understanding of the underlying biological mechanisms driving prostate cancer...
Yale University received a $1,731,409 project grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from June 2023 through May 2027 to investigate the role of immune cell-podocyte crosstalk in the pathogenesis of APOL1-FSGS and proteinuric kidney disease. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...